Evans et al. found that the risks of developing fibrosis and macular atrophy increased with greater variation in OCT retinal thickness in eyes receiving anti-VEGF therapy for nAMD, with the highest quartile of retinal thickness variability having odds ratios of 1.95 and 2.10 in developing fibrosis and geographic atrophy, respectively [17]. Here, VEGFA is linked to fibrosis.